| Past two years | Past Year | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 513 | 284 | 48 |
| Full Text Views | 9 | 2 | 0 |
| PDF Downloads | 6 | 3 | 0 |
Clinical Trials with Thiabendazole against Intestinal Nematodes Infecting Humans
K. H. Franz
K. H. Franz
College of Physicians and Surgeons, Columbia University, New York
Search for other papers by K. H. Franz in
Current site
Google Scholar
PubMed
Search for other papers by K. H. Franz in
Current site
Google Scholar
PubMed
W. J. Schneider
W. J. Schneider
College of Physicians and Surgeons, Columbia University, New York
Search for other papers by W. J. Schneider in
Current site
Google Scholar
PubMed
Search for other papers by W. J. Schneider in
Current site
Google Scholar
PubMed
M. H. Pohlman
M. H. Pohlman
College of Physicians and Surgeons, Columbia University, New York
Search for other papers by M. H. Pohlman in
Current site
Google Scholar
PubMed
Search for other papers by M. H. Pohlman in
Current site
Google Scholar
PubMed
Summary
Thiabendazole was administered orally in a suspension to 163 adults and children and found to be very effective against Ancylostoma duodenale, Ascaris lumbricoides, Necator americanus and Strongyloides stercoralis and slightly effective against Trichuris trichiura. Five treatment regimens were used and evaluated. A dosage of 25 to about 30 mg of thiabendazole per kg of body weight twice daily for 3 days was very effective and well tolerated. This was substantiated by the results obtained in a double-blind placebocontrolled study. Side effects were few with this regimen. With all treatment regimens side effects were transitory and not severe.
Author Notes
Medical Director, Firestone Plantations Company, Harbel, Liberia.
Present address: The New York Hospital, New York, New York 10021.
Present address: The Mary Imogene Bassett Hospital, Cooperstown, New York.
| Past two years | Past Year | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 513 | 284 | 48 |
| Full Text Views | 9 | 2 | 0 |
| PDF Downloads | 6 | 3 | 0 |